Publications by authors named "Alba Salguero Olid"
Objective: To adapt the GHEMA report of abemaciclib, an inhibitor of cyclin-dependent kinases 4 and 6. European Medicines Agency authorisation (April 2022) includes, in combination with endocrine therapy, the adjuvant treatment of adult patients with hormone receptor positive, human epidermal growth factor receptor 2 negative, node-positive, early breast cancer at high risk of recurrence.
Method: The efficacy and safety of abemaciclib were evaluated in a randomized, open-label and multicenter phase III study.
Objective: To adapt the GHEMA report of abemaciclib, an inhibitor of cyclin-dependent kinases 4 and 6. European Medicines Agency authorization (April 2022) includes, in combination with endocrine therapy, the adjuvant treatment of adult patients with hormone receptor positive, human epidermal growth factor receptor 2 negative, node-positive, early breast cancer at high risk of recurrence.
Method: The efficacy and safety of abemaciclib were evaluated in a randomized, open-label, and multicenter phase III study.
Objective: Preterm infants with total parenteral nutrition are at particular risk of developing carnitine deficiency with impaired tolerance of parenteral lipids. The objective was to review the scientific literature on potencial benefits of prophylactic L-carnitine administration in parenteral nutrition of preterm newborns.
Methods: Selected scientific articles in MEDLINE/PubMed, Scopus, The Cochrane Library, British Library EThOS and TESEO databases were assessed for this systematic review.